Association of Hospital Surgical Volume With Survival in Early-Stage Cervical Cancer Treated With Radical Hysterectomy.


Journal

Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101

Informations de publication

Date de publication:
01 01 2023
Historique:
received: 02 07 2022
accepted: 22 09 2022
pmc-release: 01 01 2024
entrez: 26 1 2023
pubmed: 27 1 2023
medline: 31 1 2023
Statut: ppublish

Résumé

To evaluate the association of number of radical hysterectomies performed per year in each center with disease-free survival and overall survival. We conducted an international, multicenter, retrospective study of patients previously included in the Surveillance in Cervical Cancer collaborative studies. Individuals with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IB1-IIA1 cervical cancer who underwent radical hysterectomy and had negative lymph nodes at final histology were included. Patients were treated at referral centers for gynecologic oncology according to updated national and international guidelines. Optimal cutoffs for surgical volume were identified using an unadjusted Cox proportional hazard model, with disease-free survival as the outcome and defined as the value that minimizes the P-value of the split in groups in terms of disease-free survival. Propensity score matching was used to create statistically similar cohorts at baseline. A total of 2,157 patients were initially included. The two most significant cutoffs for surgical volume were identified at seven and 17 surgical procedures, dividing the entire cohort into low-volume, middle-volume, and high-volume centers. After propensity score matching, 1,238 patients were analyzed-619 (50.0%) in the high-volume group, 523 (42.2%) in the middle-volume group, and 96 (7.8%) in the low-volume group. Patients who underwent surgery in higher-volume institutions had progressively better 5-year disease-free survival than those who underwent surgery in lower-volume centers (92.3% vs 88.9% vs 83.8%, P=.029). No difference was noted in 5-year overall survival (95.9% vs 97.2% vs 95.2%, P=.70). Cox multivariable regression analysis showed that FIGO stage greater than IB1, presence of lymphovascular space invasion, grade greater than 1, tumor diameter greater than 20 mm, minimally invasive surgical approach, nonsquamous cell carcinoma histology, and lower-volume centers represented independent risk factors for recurrence. Surgical volume of centers represented an independent prognostic factor affecting disease-free survival. Increasing number of radical hysterectomies performed in each center every year was associated with improved disease-free survival.

Identifiants

pubmed: 36701621
doi: 10.1097/AOG.0000000000005026
pii: 00006250-202301000-00023
pmc: PMC10445691
mid: NIHMS1907518
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

207-214

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

Copyright © 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Financial Disclosure Henrik Falconer reports receiving payment from Intuitive Surgical and Surgical Science. The other authors did not report any potential conflicts of interest.

Références

Int J Gynecol Cancer. 2018 Jul;28(6):1226-1231
pubmed: 29958236
Br J Surg. 2005 Apr;92(4):389-402
pubmed: 15786424
Arch Gynecol Obstet. 2021 Aug;304(2):503-510
pubmed: 33483846
Gynecol Oncol. 2022 Feb;164(2):362-369
pubmed: 34955236
J Clin Oncol. 2000 Jun;18(11):2327-40
pubmed: 10829054
Gynecol Oncol. 2015 Dec;139(3):506-12
pubmed: 26177552
Medicine (Baltimore). 2018 Dec;97(49):e13445
pubmed: 30544427
Cancer Chemother Rep. 1966 Mar;50(3):163-70
pubmed: 5910392
Gynecol Oncol. 2014 Feb;132(2):403-10
pubmed: 24361578
Cancer Res Treat. 2021 Jan;53(1):243-251
pubmed: 33070554
Ann Surg Oncol. 2012 Mar;19(3):948-58
pubmed: 21989660
Ann Surg Oncol. 2017 Oct;24(11):3406-3412
pubmed: 28785898
N Engl J Med. 2018 Nov 15;379(20):1895-1904
pubmed: 30380365
Int J Gynecol Cancer. 2020 Jan;30(1):3-14
pubmed: 31900285
J Gynecol Oncol. 2021 Mar;32(2):e24
pubmed: 33470066
Facts Views Vis Obgyn. 2021 Sep;13(3):231-239
pubmed: 34555877
Int J Gynecol Cancer. 2022 Apr 4;32(4):494-501
pubmed: 34992130
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Obstet Gynecol. 2019 Jun;133(6):1086-1098
pubmed: 31135722
Eur J Cancer. 2021 Oct 16;158:111-122
pubmed: 34666213
Gynecol Oncol. 2010 Sep;118(3):262-7
pubmed: 20573392
Obstet Gynecol. 2017 Sep;130(3):545-553
pubmed: 28796677
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Gynecol Oncol. 2021 Dec;163(3):583-592
pubmed: 34688503

Auteurs

Nicolò Bizzarri (N)

UOC Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, and the Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, and the University of Milano-Bicocca, Department of Obstetrics and Gynecology, Gynaecologic Oncology Surgical Unit, ASST-Monza, San Gerardo Hospital, Monza, Italy; the Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group, CEEGOG), and the Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, the Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, and the University Hospital Brno, Medical Faculty of Masaryk University, Brno, Czech Republic; the Center for Gynaecologic Oncology Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands; the Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru; the Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; the Baskent University School of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, and the Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health and Research Hospital, University of Health Sciences, Ankara, Turkey; Memorial Sloan Kettering Cancer Center, New York, New York; the Gynecology Oncology Center, National Institute of Cancerology Mexico, Mexico City, Mexico; the Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Bogotá, Colombia; the Wolfson Institute of Preventive Medicine, Barts Cancer Centre, Queen Mary University of London, & Barts Health NHS Trust, London, United Kingdom; the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; the Department of Gynecologic Oncology, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina; Gynecology, Medical University of Graz, Graz, Austria; the Gynecologic Oncology Unit, La Paz University Hospital - IdiPAZ, Madrid, Spain; and the Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH